Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

A perspective on monoclonal antibody therapy: Where we have been and where we are going Symposium on Monoclonal Antibody Therapy for Hematologic Malignancies - Prospects for an Integrated Therapy Approach Levy, R. W B SAUNDERS CO-ELSEVIER INC. 2000: 43–46

Abstract

The history of monoclonal antibody therapy for cancer includes many promising beginnings, a vast number of detours, and now a major success--perhaps soon to be joined by several more. Years of research by hundreds of investigators worldwide have led to a growing understanding of the principles that underlie successful monoclonal antibody therapy and that can be used to create new antibody-based agents. However, there are many remaining uncertainties about this mode of therapy, even for those agents that have already joined our therapeutic armamentarium. Several key questions will be identified and used to suggest avenues for future research.

View details for Web of Science ID 000090000300007

View details for PubMedID 11147489